Brodalumab


Article Author:
Nicole Golbari
Brandon Basehore


Article Editor:
Patrick Zito


Editors In Chief:
Sisira Reddy
Joseph Nahas
Chokkalingam Siva


Managing Editors:
Avais Raja
Orawan Chaigasame
Khalid Alsayouri
Kyle Blair
Radia Jamil
Erin Hughes
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Navid Mahabadi
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beenish Sohail
Hajira Basit
Phillip Hynes
Sandeep Sekhon


Updated:
9/30/2019 1:31:43 PM

Indications

Brodalumab is a monoclonal antibody approved by the United States Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in adult patients who have failed treatment with topical and other systemic therapy.[1][2][3] Results from phase 3 randomized, double-blinded studies have demonstrated that patients treated with brodalumab can achieve significant clinical improvement as compared to those treated with placebo. By week 12 on brodalumab, 83% of patients were able to achieve a 75% reduction in psoriasis area and severity score (PASI 75) score compared to 3% of patients on placebo, and almost 42% were able to achieve a PASI 100 response rate. Similarly, 76% of patients were able to achieve a static Physician’s Global Assessment sPGA success (defined as an sPGA score of 0 or 1).

Phase 3 studies comparing brodalumab with ustekinumab showed that at standard dosing, brodalumab was able to achieve higher rates of PASI 100, 44% and 37% versus 22% and 19% of patients treated with ustekinumab. Brodalumab is also more effective than ustekinumab in biologic-experienced patients: 40% of patients previously treated with a biologic medication were able to achieve PASI 100, while only 17% of biologic-experienced patients treated with ustekinumab were able to achieve the same level of efficacy. Additionally, brodalumab had a more rapid onset of action with PASI 75 responders reaching this benchmark in a median of 4.2 weeks compared to 9.4 weeks for ustekinumab.[4][5]

In addition to plaque psoriasis, brodalumab has been explored as a potential treatment for other auto-inflammatory diseases. A phase 2 randomized control trial examining the efficacy of brodalumab for the treatment of psoriatic arthritis (PsA) showed that by week 12 almost 40% of patients treated with brodalumab (at either 140 mg or 280 mg doses) were able to achieve 20% improvement in the American College of Rheumatology response criteria (ACR 20) compared to 18% in the placebo group. By 24 weeks, 51% of patients in the 140 mg brodalumab group and 64% of those in the 280 mg group achieved improved ACR 20 response. The research revealed no statistical difference in response among patients who had received prior treatment with a biologic medication.

While results from PsA trials have been promising, phase 1b and phase 2 data evaluating brodalumab efficacy in subjects with rheumatoid arthritis who have had an inadequate response to methotrexate have not demonstrated evidence of clinical response. There is no evidence of significant improvement in ACR or disease activity scores for patients treated with brodalumab compared to placebo. Similarly, though the interleukin-17 (IL-17) pro-inflammatory pathways have been implicated in airway hypersensitivity reactions, brodalumab has not demonstrated effectiveness in the treatment of moderate to severe asthma.

Mechanism of Action

Brodalumab is a human monoclonal IgG2 antibody directed at the IL-17 receptor. The IL-17 protein family is a group of six pro-inflammatory cytokines (IL17A-F) produced by T-helper cells (Th17) thought to play an important role in auto-inflammatory diseases such as psoriasis, PsA, rheumatoid arthritis, and multiple sclerosis.[6] Unlike other IL-17 inhibitors, such as ixekizumab and secukinumab, which primarily target IL-17A and bind to the protein itself, brodalumab targets the IL-17RA receptor. The IL-17RA receptor is used not only by IL-17A, but also by IL-17C, IL17-E, and IL-17F.  By blocking the IL-17RA receptor, brodalumab prevents the release of IL-17 mediated pro-inflammatory protein kinases and chemokines, such as nuclear factor kappa light chain enhancer of activated B cells (NF-kappa-B), IL-6, IL-8, cyclooxygenase-2 (COX-2), matrix metalloproteinases (MMPs), and granulocyte-macrophage colony-stimulating factor (GM-CSF).

Administration

Brodalumab administration is by subcutaneous injection. Patients may self-inject the 210 mg/1.5ml prefilled syringe at intervals of week 0, 1, and 2, followed by an injection every two weeks. Prefilled syringes should be stored at 2 degrees C to 8 degrees C, but should be given approximately 30 minutes to reach room temperature before injection. Syringes may be stored at room temperature for up to 2 weeks, but should not be re-refrigerated. If there is an inadequate response by weeks 12 to 16 of treatment, discontinue brodalumab as therapy past 16 weeks is unlikely to result in more significant disease improvement.

Adverse Effects

As brodalumab is an immune-modulating medication, most adverse reactions to therapy relate to increased risk of infection.[7][8][9] The most common adverse events reported at week 120 of an open-label extension study in patients receiving brodalumab included:

  • Nasopharyngitis (27%)
  • Upper respiratory tract infections (20%)
  • Arthralgia (16%)
  • Back pain (11%)
  • Gastroenteritis (10%)
  • Influenza (9%)
  • Oropharyngeal pain (9%) 
  • Sinusitis (9%)

Mild to moderate oral candidiasis was noted in five patients (3%), and there were reports of injection site reactions in fifteen patients (8%). Additionally, a total of 15 patients (8%) reported serious adverse events. Four patients had to withdraw treatment due to infection. Transient grade-2 absolute neutrophil abnormalities occurred in four patients (2%), but all cases resolved without modification in treatment. Several cases of grade-3 neutropenia have also been reported.

Furthermore, while not directly establishing a causal relationship, four completed suicides, including one case ruled as indeterminate, were reported in patients receiving brodalumab during phase 3 clinical trials. Therefore, package inserts for brodalumab include a boxed warning for increased risk of suicidal ideation and behavior. Patients must be informed about this increased risk and should receive a referral to a mental health professional in the event of new or increasing thoughts of suicide or depression. Brodalumab is only available through a Risk Evaluation and Mitigation Strategy (REMS) program.

Contraindications

Inflammatory Bowel Disease

  •  Brodalumab is contraindicated in patients with Crohn disease. Researchers terminated a randomized, placebo-controlled trial examining the safety and efficacy of brodalumab in patients with Crohn disease due to disproportionate Crohn disease progression in those patients treated with brodalumab: 31% experienced worsening of disease versus 9% in the placebo group. Additionally, though patients with Crohn disease met the exclusion criteria from the psoriasis clinical trials, during one phase 3 study, one patient developed new-onset Crohn disease. If a patient develops Crohn disease while taking brodalumab, they should discontinue therapy.

Infection

  • Risks and benefits of treatment with brodalumab require thoughtful evaluation before administration in patients with chronic or recurrent infections. If a patient develops a non-resolving infection, the clinician should discontinue the medication.

Children and Pregnancy

  • Though no contraindication exists, the efficacy and safety of brodalumab have not yet been investigated as a potential treatment in children or pregnant women with psoriasis or breastfed infants of mothers taking brodalumab. However, monoclonal antibodies are generally known to actively be transported through the placenta, especially in the third trimester and get excreted in modest amounts in breast milk. Risks and benefits to the mother should be assessed prior to initiation or discontinuation of brodalumab.

Monitoring

Due to increased risk of infection in patients prescribed brodalumab, all patients require screening for tuberculosis (TB) before initiation of the medication. If a patient has an active TB infection, the clinician should not administer the drug. For patients with latent TB or a history of latent or active TB with unconfirmed treatment, therapy for TB infection should start prior to the initiation of brodalumab as there is a risk for latent TB reactivation.[10]

Patients should be informed of the increased risk of neutropenia and will need monitoring for any new or non-resolving infections. Additionally, live vaccines should be avoided in patients while they are taking brodalumab.

Enhancing Healthcare Team Outcomes

The management of patients with psoriasis is usually by the primary care provider, nurse practitioner, dermatologist, infectious disease consultant, internist, and a rheumatologist. When the disease is moderate to severe, one option for treatment is brodalumab. This new agent was approved by the United States Food and Drug Administration for the treatment of moderate to severe plaque psoriasis in adult patients who have failed treatment with topical and other systemic therapy. The drug is effective and does provide rapid symptom relief, but monitoring of patients is necessary.

Due to increased risk of infection in patients prescribed brodalumab, all patients require screening for tuberculosis (TB) prior to initiation of the medication. If a patient has an active TB infection, the drug should not be administered. For patients with latent TB or a history of latent or active TB with unconfirmed treatment, therapy for TB infection should start before the initiation of brodalumab as there is a risk for latent TB reactivation.

Patients should be informed of the increased risk of neutropenia and must have ongoing monitoring for any new or non-resolving infections. Additionally, live vaccines should be avoided in patients while they are taking brodalumab. Pharmacists should carefully verify dosing and perform complete medication reconciliation for patients commencing therapy on brodalumab, and report any concerns to the healthcare team. 

Nursing staff can assist in all the above monitoring activities, help evaluate the effectiveness of ongoing treatment, and also confirm patient compliance. Should they note any issues, these must be reported to the prescribing physician immediately.

Because of its adverse event profile and potential for increased infections, brodalumab treatment requires an interprofessional team approach, including physicians, specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results. [Level V]


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Brodalumab - Questions

Take a quiz of the questions on this article.

Take Quiz
A 35-year-old man with moderate plaque psoriasis receives treatment with brodalumab. Which of the following should be monitored in a patient on brodalumab?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is the mechanism of action of brodalumab?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 35-year-old pregnant patient with a history of plaque psoriasis, psoriatic arthritis, Crohn disease and untreated latent tuberculosis has failed previous topical, phototherapy, and systemic treatments for psoriasis. Which of the following is a contraindication to starting brodalumab therapy?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
For which of the following autoimmune diseases is brodalumab FDA indicated?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following patients is a candidate for therapy with brodalumab?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Brodalumab - References

References

Beck KM,Koo J, Brodalumab for the treatment of plaque psoriasis: up-to-date. Expert opinion on biological therapy. 2019 Mar 4;     [PubMed]
Pinter A,Wilsmann-Theis D,Peitsch WK,Mössner R, Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases. The Journal of dermatology. 2019 Feb 20;     [PubMed]
Lynde CW,Beecker J,Dutz J,Flanagan C,Guenther LC,Gulliver W,Papp K,Rahman P,Sholter D,Searles GE, Treating to Target(s) With Interleukin-17 Inhibitors. Journal of cutaneous medicine and surgery. 2019 Mar/Apr;     [PubMed]
Timmermann S,Hall A, Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis. Basic     [PubMed]
Loos AM,Liu S,Segel C,Ollendorf DA,Pearson SD,Linder JA, Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis. Journal of the American Academy of Dermatology. 2018 Jul;     [PubMed]
Silfvast-Kaiser A,Paek SY,Menter A, Anti-IL17 therapies for psoriasis. Expert opinion on biological therapy. 2018 Nov 30;     [PubMed]
McMichael A,Desai SR,Qureshi A,Rastogi S,Alexis AF, Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials. American journal of clinical dermatology. 2018 Nov 23;     [PubMed]
Sondag M,Verhoeven F,Guillot X,Prati C,Wendling D, Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review. Clinical rheumatology. 2019 Feb;     [PubMed]
Hashim PW,Chen T,Lebwohl MG,Marangell LB,Kircik LH, What Lies Beneath the Face Value of a BOX WARNING: A Deeper Look at Brodalumab. Journal of drugs in dermatology : JDD. 2018 Aug 1;     [PubMed]
Kaushik SB,Lebwohl MG, Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. Journal of the American Academy of Dermatology. 2019 Jan;     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Rheumatology. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Rheumatology, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Rheumatology, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Rheumatology. When it is time for the Rheumatology board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Rheumatology.